GenEmbryomics provides Panacea GenomeScreen™, a preimplantation genetic testing solution using whole genome sequencing (PGT-WGS). This platform detects both chromosomal abnormalities and inherited/de novo genetic mutations, enabling IVF clinicians to select embryos with a reduced risk of genetic disease.
Funding
Funding not disclosed
Founders
Product
Problem
Standard preimplantation genetic testing (PGT) primarily identifies chromosomal abnormalities, leaving a significant gap in detecting inherited and de novo genetic mutations that can lead to severe diseases. This oversight impacts IVF success rates and the long-term health of offspring.
Solution
GenEmbryomics offers Panacea GenomeScreen™, a comprehensive preimplantation genetic testing solution utilizing whole genome sequencing (PGT-WGS). This advanced platform goes beyond aneuploidy screening to detect a wide spectrum of inherited and new genetic mutations. By providing detailed genetic insights, GenEmbryomics empowers IVF clinicians and their patients to select embryos with the lowest risk profile for genetic disease. The technology aims to increase IVF success and contribute to healthier family outcomes by offering a more complete genetic assessment.
Target Audience
Primary customers are IVF clinics and genetic testing laboratories seeking to enhance their preimplantation genetic testing services with advanced whole genome sequencing capabilities.
Features
- Whole genome sequencing (PGT-WGS) for comprehensive genetic mutation detection.
- Identification of both chromosomal abnormalities (aneuploidy, mosaicism) and single-gene mutations.
- Proprietary analytical pipeline for detailed genetic variant interpretation.
- Generation of clear, actionable reports for clinical decision-making.
- Designed to integrate with existing IVF laboratory workflows.